Generic Name and Formulations:
Dulaglutide 0.75mg/0.5mL, 1.5mg/0.5mL; per pen; soln for SC inj.
Lilly, Eli and Company
Indications for TRULICITY:
Adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes.
Limitations Of use:
Not recommended as first-line treatment for patients inadequately controlled on diet and exercise. Not studied in patients with history of pancreatitis. Not for treating type 1 diabetes or diabetic ketoacidosis. Not a substitute for insulin. Not recommended in patients with pre-existing severe GI disease.
Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥18yrs: initially 0.75mg once weekly; may increase to max 1.5mg once weekly if inadequate response.
<18yrs: not recommended.
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Risk of thyroid C-cell tumors.
Risk of thyroid C-cell tumors; inform patients of risk and symptoms. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of pancreatitis; consider alternative antidiabetics. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Renal impairment: caution with initiating or escalating doses. Monitor renal function in renally-impaired patients reporting severe GI reactions. ESRD. Hepatic impairment. Pregnancy. Nursing mothers.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Increased risk of hypoglycemia with concomitant sulfonylureas or insulin; consider reducing their doses. May affect absorption of other oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.
Nausea, diarrhea, vomiting, abdominal pain, decreased appetite; pancreatitis, hypersensitivity reactions (discontinue if occur), acute kidney injury.
Renal and Urology News Articles
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Higher Push-Up Capacity Linked to Lower Incidence of CVD Events
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer
- Dialysis and Transplant Patients at Increased Risk for Cancer Death
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)